Canada markets close in 40 minutes

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.13500.0000 (0.00%)
As of 03:09PM EDT. Market open.
Full screen
Previous Close0.1350
Bid0.1350 x N/A
Ask0.1400 x N/A
Day's Range0.1350 - 0.1350
52 Week Range0.1000 - 0.2500
Avg. Volume15,803
Market Cap9.427M
Beta (5Y Monthly)-0.48
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • News Direct

    Rakovina Therapeutics receives government grant to accelerate novel cancer therapy program

    Rakovina Therapeutics chief scientific officer Mads Daugaard joined Proactive's Steve Darling to share news the company is receiving research and development funding from the National Research Coun...

  • GlobeNewswire

    Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies

    VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is receiving advisory services and up to $122,865 in non-dilutive research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). Funding will support Rakovina Therapeutics scientists in the development of assays and animal models for evaluation of the Company’s novel classes of DNA-

  • GlobeNewswire

    Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates

    VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend the expiry date of 11,414,750 common share purchase warrants (the “Warrants”) issued by the Company. The original term of the Warrants was two years and they currently expire on March 25, 2023. The Company proposes to extend the expiry date by up to 12 months (the “Warrant Extension”). No other terms o